RE: pipe and dec.InNexus Biotechnology Inc. (OTCBB: IXSBF - News)(TSX VENTURE: IXS - News), (https://www.ixsbio.com) Chairman and CEO, Jeff Morhet will host a webcast teleconference on Monday, February 11, 2008 at 11:00 AM ET to discuss recent announcement with Royalty Pharma and preliminary results of an in vivo animal study exhibiting DXL625 (CD20)'s efficacy in reducing the growth rate of lymphoma cancer tumors. InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL antibodies utilize unique, novel and patented methods and technologies of InNexus.